Inactive

COMBINED SYNOPSIS / SOLICITATION 75A50122Q00005 TITLE: Acquisition of Filovirus Point-of-Care (PoC) Diagnostic Tests (i) This is a combined synopsis/solicitation for commercial items prepared in accor... COMBINED SYNOPSIS / SOLICITATION 75A50122Q00005 TITLE: Acquisition of Filovirus Point-of-Care (PoC) Diagnostic Tests (i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested. (ii) The solicitation number is 75A50122Q00005 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures; FAR Subpart 13.5—Simplified Procedures for Certain Commercial Items; and FAR Part 12—Acquisition of Commercial Items, and is expected to exceed the simplified acquisition threshold. (iii) This is a competitive combined synopsis/solicitation. Award(s) will be made to the offerors whose quote(s) successfully address each of the identified requirements, and for which the proposed price is determined to be fair and reasonable. (iv) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) Number 2022-03, with effective date January 1, 2022. (v) The associated NAICS code 325413 - In-Vitro Diagnostic Substance Manufacturing and the small business size standard is 1,250 employees. This requirement has no set-aside restrictions.